Also, while the distinction in sensitivity between BRCA1 and BRCA2-associated ovarian cancers remains unclear in the clinical setting, emerging in vitro data does indicate that all BRCA mutations are not equal in their functionality. This evidence concerns the gene BRCA1 and ovarian carcinoma.